CN106102762A - 治疗脑部病症或鉴定与其相关的生物标记的方法 - Google Patents

治疗脑部病症或鉴定与其相关的生物标记的方法 Download PDF

Info

Publication number
CN106102762A
CN106102762A CN201480068036.1A CN201480068036A CN106102762A CN 106102762 A CN106102762 A CN 106102762A CN 201480068036 A CN201480068036 A CN 201480068036A CN 106102762 A CN106102762 A CN 106102762A
Authority
CN
China
Prior art keywords
disorder
patient
brain
glyx
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480068036.1A
Other languages
English (en)
Chinese (zh)
Inventor
J·莫斯卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NORTHWEST UNIVERSITY
Original Assignee
NORTHWEST UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NORTHWEST UNIVERSITY filed Critical NORTHWEST UNIVERSITY
Priority to CN202010314939.0A priority Critical patent/CN111920412A/zh
Publication of CN106102762A publication Critical patent/CN106102762A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
CN201480068036.1A 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法 Pending CN106102762A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010314939.0A CN111920412A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915835P 2013-12-13 2013-12-13
US61/915,835 2013-12-13
PCT/US2014/070340 WO2015089503A2 (en) 2013-12-13 2014-12-15 Methods of treating brain disorders or identifying biomarkers related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010314939.0A Division CN111920412A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法

Publications (1)

Publication Number Publication Date
CN106102762A true CN106102762A (zh) 2016-11-09

Family

ID=53371976

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480068036.1A Pending CN106102762A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法
CN202010314939.0A Pending CN111920412A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010314939.0A Pending CN111920412A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法

Country Status (9)

Country Link
US (1) US20160345855A1 (enExample)
EP (2) EP3721799A1 (enExample)
JP (2) JP2017500306A (enExample)
CN (2) CN106102762A (enExample)
AU (2) AU2014361822A1 (enExample)
CA (1) CA2933372A1 (enExample)
IL (2) IL246148A0 (enExample)
MX (1) MX2016007716A (enExample)
WO (1) WO2015089503A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110123342A (zh) * 2019-04-17 2019-08-16 西北大学 一种基于脑电波的网瘾检测方法及系统

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3362080A1 (en) * 2015-10-16 2018-08-22 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
CN113557028A (zh) * 2019-01-11 2021-10-26 诺雷克斯股份有限公司 雷帕替奈的盐和晶型

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050273017A1 (en) * 2004-03-26 2005-12-08 Evian Gordon Collective brain measurement system and method
WO2007123799A2 (en) * 2006-04-03 2007-11-01 The Trustees Of The University Of Pennsylvania Assessing subject's reactivity to psychological stress using fmri
CA2659099A1 (en) * 2006-06-15 2007-12-21 Mars, Incorporated Use of cocoa flavanols and procyanidins to improve executive cognitive and cerebral blood flow
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
HRP20140784T1 (hr) * 2009-10-05 2014-10-10 Northwestern University Glyx-13 za uporabu u postupku tretiranja refraktornih depresija
BR112013027554A2 (pt) * 2011-04-27 2016-09-06 Univ Northwestern "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
JP2015505314A (ja) * 2012-01-09 2015-02-19 武田薬品工業株式会社 アルツハイマー病を治療する方法及び医薬品

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NIH: "Functional Neuroimaging Effects of the N-methyl-D-aspartate Receptor (NMDAR) Partial Agonist, GLYX-13, on Learning and Memory in Healthy Individuals"", 《NCT01844726》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110123342A (zh) * 2019-04-17 2019-08-16 西北大学 一种基于脑电波的网瘾检测方法及系统

Also Published As

Publication number Publication date
EP3079579A2 (en) 2016-10-19
AU2019264583A1 (en) 2019-12-05
JP2020007333A (ja) 2020-01-16
WO2015089503A3 (en) 2015-10-01
EP3721799A1 (en) 2020-10-14
US20160345855A1 (en) 2016-12-01
JP2017500306A (ja) 2017-01-05
EP3079579A4 (en) 2017-07-19
IL276431A (en) 2020-09-30
IL246148A0 (en) 2016-07-31
AU2014361822A1 (en) 2016-07-28
MX2016007716A (es) 2017-03-31
CA2933372A1 (en) 2015-06-18
CN111920412A (zh) 2020-11-13
WO2015089503A2 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
US12409176B2 (en) Methods of treating acute depression
JP6953468B2 (ja) 新規の使用
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
WO2011044089A2 (en) Methods of treating depression and other related diseases
US20110034565A1 (en) Psycho-pharmaceuticals
JP2020128391A (ja) Ｎｍｄａ調節剤を使用するうつ病の治療方法
AU2019264583A1 (en) Treating brain disorders and biomarkers related thereto
US20120046302A1 (en) Methods of treating cns disorders
TW201211021A (en) Methods of use of cyclic amide derivatives to treat schizophrenia
WO2010126527A1 (en) Methods of treating cns disorders
EP4417258A2 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
HK40040750A (en) Methods of treating brain disorders or identifying biomarkers related thereto
AU4301699A (en) Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders
EP3856195A1 (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
Zare et al. Wake-Promoting agents; insights into clinical use and molecular perspectives
KR20240043126A (ko) 아리피프라졸 및 미르타자핀을 유효성분으로 포함하는 정서행동장애 치료용 조성물
EP3082798B1 (en) Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity
JP2022510363A (ja) （ｒ）－２－（２－オキソピロリジン－１－イル）ブタンアミドと（ｓ）－２－（２－オキソピロリジン－１－イル）ブタンアミドを非ラセミ比で含む相乗的組成物
Street et al. Reduction of psychotic symptoms in patients with Lewy Body-like symptoms treated with olanzapine
Hemmeter et al. P. 5. a. 009 Effects of long term treatment with cholinesterase inhibitors on sleep EEG in patients with dementia of Alzheimer and frontotemporal type
HK1237649A1 (zh) Nmdar调节化合物的组合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161109